Cargando…
Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT
Cefazolin is a recommended treatment for methicillin-susceptible Staphylococcus aureus (MSSA) infections that has been successfully used in outpatient parenteral antibiotic therapy (OPAT) programs. The aim of this study was to assess the clinical outcomes of cefazolin delivered each day (Group 24) v...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950875/ https://www.ncbi.nlm.nih.gov/pubmed/35329878 http://dx.doi.org/10.3390/jcm11061551 |
_version_ | 1784675247863103488 |
---|---|
author | Herrera-Hidalgo, Laura Luque-Márquez, Rafael de Alarcon, Aristides Guisado-Gil, Ana Belén Gutierrez-Gutierrez, Belen Navarro-Amuedo, Maria Dolores Praena-Segovia, Julia Carmona-Caballero, Juan Manuel Fraile-Ramos, Elena Gutierrez-Valencia, Alicia Lopez-Cortes, Luis Eduardo Gil-Navarro, Maria Victoria |
author_facet | Herrera-Hidalgo, Laura Luque-Márquez, Rafael de Alarcon, Aristides Guisado-Gil, Ana Belén Gutierrez-Gutierrez, Belen Navarro-Amuedo, Maria Dolores Praena-Segovia, Julia Carmona-Caballero, Juan Manuel Fraile-Ramos, Elena Gutierrez-Valencia, Alicia Lopez-Cortes, Luis Eduardo Gil-Navarro, Maria Victoria |
author_sort | Herrera-Hidalgo, Laura |
collection | PubMed |
description | Cefazolin is a recommended treatment for methicillin-susceptible Staphylococcus aureus (MSSA) infections that has been successfully used in outpatient parenteral antibiotic therapy (OPAT) programs. The aim of this study was to assess the clinical outcomes of cefazolin delivered each day (Group 24) vs. every two days (Group 48) for MSSA infections in OPAT programs. It was a prospective observational study with retrospective analysis of a cohort of MSSA infections attended in OPAT. The primary outcome was treatment success, defined as completing the antimicrobial regimen without death, treatment discontinuation, or readmission during treatment and follow-up. A univariate and multivariate logistic regression model was built. A two-sided p < 0.05 was considered statistically significant. Of the 149 MSSA infections treated with cefazolin 2 g/8 h in OPATs, 94 and 55 patients were included in the delivery Group 24 and Group 48, respectively. Treatment failure and unplanned readmission rates were similar in both groups (11.7% vs. 7.3% p = 0.752 and 8.5% vs. 5.5% p = 0.491). There was a significant increase in vascular access complications in Group 24 (33.0%) with respect to Group 48 (7.3%) (p < 0.001). Treating uncomplicated MSSA infection with cefazolin home-delivered every two days through an OPAT program is not associated with an increased risk of treatment failure and entails a significant reduction in resource consumption compared to daily delivery. |
format | Online Article Text |
id | pubmed-8950875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89508752022-03-26 Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT Herrera-Hidalgo, Laura Luque-Márquez, Rafael de Alarcon, Aristides Guisado-Gil, Ana Belén Gutierrez-Gutierrez, Belen Navarro-Amuedo, Maria Dolores Praena-Segovia, Julia Carmona-Caballero, Juan Manuel Fraile-Ramos, Elena Gutierrez-Valencia, Alicia Lopez-Cortes, Luis Eduardo Gil-Navarro, Maria Victoria J Clin Med Article Cefazolin is a recommended treatment for methicillin-susceptible Staphylococcus aureus (MSSA) infections that has been successfully used in outpatient parenteral antibiotic therapy (OPAT) programs. The aim of this study was to assess the clinical outcomes of cefazolin delivered each day (Group 24) vs. every two days (Group 48) for MSSA infections in OPAT programs. It was a prospective observational study with retrospective analysis of a cohort of MSSA infections attended in OPAT. The primary outcome was treatment success, defined as completing the antimicrobial regimen without death, treatment discontinuation, or readmission during treatment and follow-up. A univariate and multivariate logistic regression model was built. A two-sided p < 0.05 was considered statistically significant. Of the 149 MSSA infections treated with cefazolin 2 g/8 h in OPATs, 94 and 55 patients were included in the delivery Group 24 and Group 48, respectively. Treatment failure and unplanned readmission rates were similar in both groups (11.7% vs. 7.3% p = 0.752 and 8.5% vs. 5.5% p = 0.491). There was a significant increase in vascular access complications in Group 24 (33.0%) with respect to Group 48 (7.3%) (p < 0.001). Treating uncomplicated MSSA infection with cefazolin home-delivered every two days through an OPAT program is not associated with an increased risk of treatment failure and entails a significant reduction in resource consumption compared to daily delivery. MDPI 2022-03-11 /pmc/articles/PMC8950875/ /pubmed/35329878 http://dx.doi.org/10.3390/jcm11061551 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Herrera-Hidalgo, Laura Luque-Márquez, Rafael de Alarcon, Aristides Guisado-Gil, Ana Belén Gutierrez-Gutierrez, Belen Navarro-Amuedo, Maria Dolores Praena-Segovia, Julia Carmona-Caballero, Juan Manuel Fraile-Ramos, Elena Gutierrez-Valencia, Alicia Lopez-Cortes, Luis Eduardo Gil-Navarro, Maria Victoria Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT |
title | Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT |
title_full | Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT |
title_fullStr | Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT |
title_full_unstemmed | Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT |
title_short | Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT |
title_sort | clinical outcomes of an innovative cefazolin delivery program for mssa infections in opat |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950875/ https://www.ncbi.nlm.nih.gov/pubmed/35329878 http://dx.doi.org/10.3390/jcm11061551 |
work_keys_str_mv | AT herrerahidalgolaura clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat AT luquemarquezrafael clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat AT dealarconaristides clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat AT guisadogilanabelen clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat AT gutierrezgutierrezbelen clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat AT navarroamuedomariadolores clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat AT praenasegoviajulia clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat AT carmonacaballerojuanmanuel clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat AT fraileramoselena clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat AT gutierrezvalenciaalicia clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat AT lopezcortesluiseduardo clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat AT gilnavarromariavictoria clinicaloutcomesofaninnovativecefazolindeliveryprogramformssainfectionsinopat |